Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Cediranib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Oct 2015 Planned primary completion date changed from 1 Jan 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
- 17 Oct 2013 Planned end date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.